Seres Therapeutics reports Q1 2026 loss, advances live biotherapeutics with key clinical data pending

Seres Therapeutics reported a net loss of $19.9 million for Q1 2026, down from a net income of $32.7 million in Q1 2025, mainly due to the absence of a $50 million payment from Nestlé related to the VOWST sale. The company is progressing its live biotherapeutic pipeline, including SER-155 for immune checkpoint inhibitor-related enterocolitis and bloodstream infection prevention in blood cancer patients, and SER-603 for inflammatory bowel disease. Clinical data from an investigator-sponsored trial of SER-155 is expected soon, which could expand its therapeutic applications. Seres is actively seeking partnerships and funding to support further development and extend its cash runway beyond Q3 2026.